Cetani F, Picone A, Cerrai P, Vignali E, Borsari S, Pardi E, Viacava P, Naccarato A G, Miccoli P, Kifor O, Brown E M, Pinchera A, Marcocci C
Dipartimento di Endocrinologia e Metabolismo, Ortopedia e Medicina del Lavoro, Università di Pisa, 56125 Pisa, Italy.
J Clin Endocrinol Metab. 2000 Dec;85(12):4789-94. doi: 10.1210/jcem.85.12.7028.
A reduced expression of calcium-sensing receptor (CaR) messenger ribonucleic acid and protein accompanied by abnormalities in parathyroid cell proliferation and PTH secretion are present in primary hyperparathyroidism. We studied the expression of CaR protein by immunohistochemistry in 36 sporadic parathyroid adenomas and investigated the relationship between CaR expression and several preoperative clinical parameters, including the set-point of Ca(2+)-regulated PTH secretion (measured in vivo). The adenomas were classified in 4 categories according to the intensity of immunohistochemical staining: 5 (14%) showed a CaR staining intensity similar to that of normal parathyroid ( ), 10 (27%) showed moderate staining (++), 16 (45%) showed weak staining (+), and 5 (14%) were negative (-). The intensity of CaR staining was not related to preoperative serum Ca(2+), PTH levels or adenoma volume. Twenty-nine patients underwent preoperatively the calcium infusion test to evaluate the PTH-Ca(2+) set-point. Individual values of PTH-Ca(2+) set-point ranged from 1.38-1.93 mmol/L and were significantly correlated with basal Ca(2+) levels (r = 0.96; P: = 0. 0001) and adenoma volume (r = 0.5; P: = 0.01). The mean PTH-Ca(2+) set-point values were significantly different in the 4 groups of patients classified according to immunohistochemical staining intensity of their adenoma (P: = 0.025; F = 3.78); the mean PTH-Ca(2+) set-point was significantly higher in the groups classified as negative than in those classified as weak or moderate. No correlation was observed between the PTH-Ca(2+) set-point and basal PTH levels or between the percent maximal PTH inhibition and adenoma volume and basal PTH or Ca(2+) levels. In summary, our data suggest that there is a relationship between apparent CaR protein expression and PTH-Ca(2+) set-point abnormality, suggesting that a reduced receptor content might have an important role in the pathogenesis of primary hyperparathyroidism.
原发性甲状旁腺功能亢进症存在钙敏感受体(CaR)信使核糖核酸和蛋白质表达降低,并伴有甲状旁腺细胞增殖及甲状旁腺激素(PTH)分泌异常。我们采用免疫组织化学方法研究了36例散发性甲状旁腺腺瘤中CaR蛋白的表达情况,并探讨了CaR表达与术前一些临床参数之间的关系,包括钙调节PTH分泌的设定点(体内测量)。根据免疫组织化学染色强度,腺瘤被分为4类:5例(14%)显示CaR染色强度与正常甲状旁腺相似( ),10例(27%)显示中度染色(++),16例(45%)显示弱染色(+),5例(14%)为阴性(-)。CaR染色强度与术前血清钙、PTH水平或腺瘤体积无关。29例患者术前进行了钙输注试验以评估PTH-钙设定点。PTH-钙设定点的个体值范围为1.38 - 1.93 mmol/L,与基础钙水平显著相关(r = 0.96;P = 0.0001)及腺瘤体积相关(r = 0.5;P = 0.01)。根据腺瘤免疫组织化学染色强度分类的4组患者中,平均PTH-钙设定点值有显著差异(P = 0.025;F = 3.78);阴性组的平均PTH-钙设定点显著高于弱染色或中度染色组。未观察到PTH-钙设定点与基础PTH水平之间的相关性,也未观察到最大PTH抑制百分比与腺瘤体积及基础PTH或钙水平之间的相关性。总之,我们的数据表明,CaR蛋白的表观表达与PTH-钙设定点异常之间存在关联,提示受体含量降低可能在原发性甲状旁腺功能亢进症的发病机制中起重要作用。